|
US5093330A
(en)
|
1987-06-15 |
1992-03-03 |
Ciba-Geigy Corporation |
Staurosporine derivatives substituted at methylamino nitrogen
|
|
US6605712B1
(en)
|
1990-12-20 |
2003-08-12 |
Arch Development Corporation |
Gene transcription and ionizing radiation: methods and compositions
|
|
JP2001523958A
(ja)
|
1997-03-21 |
2001-11-27 |
ブライハム アンド ウィミンズ ホスピタル，インコーポレイテッド |
免疫療法のｃｔｌａ−４結合ペプチド
|
|
EP1210428B1
(en)
|
1999-08-23 |
2015-03-18 |
Dana-Farber Cancer Institute, Inc. |
Pd-1, a receptor for b7-4, and uses therefor
|
|
IL148079A0
(en)
|
1999-08-24 |
2002-09-12 |
Medarex Inc |
Human ctla-4 antibodies and compositions containing the same
|
|
ES2350687T3
(es)
|
2002-07-03 |
2011-01-26 |
Ono Pharmaceutical Co., Ltd. |
Composiciones de inmunopotenciación.
|
|
RU2494107C2
(ru)
|
2005-05-09 |
2013-09-27 |
Оно Фармасьютикал Ко., Лтд. |
Моноклональные антитела человека к белку программируемой смерти 1 (pd-1) и способы лечения рака с использованием анти-pd-1-антител самостоятельно или в комбинации с другими иммунотерапевтическими средствами
|
|
HRP20131167T1
(hr)
|
2007-06-18 |
2014-01-03 |
Merck Sharp & Dohme B.V. |
Antitijela za humani receptor programirane smrti pd-1
|
|
AR072999A1
(es)
|
2008-08-11 |
2010-10-06 |
Medarex Inc |
Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
|
|
CN102203132A
(zh)
|
2008-08-25 |
2011-09-28 |
安普利穆尼股份有限公司 |
Pd-1拮抗剂的组合物和使用方法
|
|
US20100069340A1
(en)
*
|
2008-09-11 |
2010-03-18 |
Wyeth |
Pharmaceutical compositions of an src kinase inhibitor and an aromatase inhibitor
|
|
AU2009333580B2
(en)
|
2008-12-09 |
2016-07-07 |
Genentech, Inc. |
Anti-PD-L1 antibodies and their use to enhance T-cell function
|
|
JP4965623B2
(ja)
|
2009-09-30 |
2012-07-04 |
インターナショナル・ビジネス・マシーンズ・コーポレーション |
所定のソフトウェアの実行パラメータを入力フィールドへ入力することを支援するための方法、システム、およびプログラム
|
|
US8907053B2
(en)
|
2010-06-25 |
2014-12-09 |
Aurigene Discovery Technologies Limited |
Immunosuppression modulating compounds
|
|
US8841418B2
(en)
|
2011-07-01 |
2014-09-23 |
Cellerant Therapeutics, Inc. |
Antibodies that specifically bind to TIM3
|
|
WO2013043569A1
(en)
|
2011-09-20 |
2013-03-28 |
Vical Incorporated |
Synergistic anti-tumor efficacy using alloantigen combination immunotherapy
|
|
HRP20201595T1
(hr)
|
2011-11-28 |
2020-12-11 |
Merck Patent Gmbh |
Anti-pd-l1 protutijela i njihova uporaba
|
|
US8916709B2
(en)
*
|
2012-03-30 |
2014-12-23 |
Cubist Pharmaceuticals, Inc. |
1,2,4-oxadiazole and 1,2,4-thiadiazole β-lactamase inhibitors
|
|
CN113967253A
(zh)
|
2012-05-15 |
2022-01-25 |
百时美施贵宝公司 |
通过破坏pd-1/pd-l1信号传输的免疫治疗
|
|
AR091649A1
(es)
|
2012-07-02 |
2015-02-18 |
Bristol Myers Squibb Co |
Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y sus usos
|
|
CA2916638C
(en)
|
2012-07-31 |
2021-01-12 |
The Brigham And Women's Hospital, Inc. |
Modulation of the immune response
|
|
EA037554B1
(ru)
|
2013-03-15 |
2021-04-13 |
Глаксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед |
Анти-lag-3 связывающие белки
|
|
NZ718821A
(en)
|
2013-09-11 |
2022-07-01 |
Medimmune Ltd |
Anti-b7-h1 antibodies for treating tumors
|
|
US20150259420A1
(en)
|
2014-03-14 |
2015-09-17 |
Novartis Ag |
Antibody molecules to lag-3 and uses thereof
|
|
EP3328374A4
(en)
*
|
2015-07-31 |
2019-03-13 |
The Johns Hopkins University |
GLUTAMINANTAGONISTS FOR THE TREATMENT OF COGNITIVE DEFICITES
|
|
CA2994165A1
(en)
*
|
2015-07-31 |
2017-02-09 |
The Johns Hopkins University |
Methods for cancer and immunotherapy using glutamine analogues, including don
|
|
AU2016302940B2
(en)
|
2015-07-31 |
2021-02-04 |
The Johns Hopkins University |
Prodrugs of glutamine analogs
|
|
SG11202107317WA
(en)
*
|
2019-01-18 |
2021-08-30 |
Dracen Pharmaceuticals Inc |
Combinaton therapy with a don prodrug and an immune checkpoint inhibitor
|
|
JP2022519574A
(ja)
*
|
2019-02-11 |
2022-03-24 |
ドラセン ファーマシューティカルズ インコーポレイテッド |
Ｌ－グルタミン酸からｄｏｎプロドラッグを調製する方法
|
|
US11760723B2
(en)
|
2019-02-11 |
2023-09-19 |
Dracen Pharmaceuticals, Inc. |
Method of preparing a DON prodrug from L-pyroglutamic acid
|